Altimmune, Inc. develops pemvidutide, a late clinical-stage dual-action therapy targeting glucagon and GLP-1 receptors for serious liver diseases. Company news centers on pemvidutide development in metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), including clinical trial updates and FDA designations such as Fast Track and Breakthrough Therapy Designation where granted.
Altimmune updates also cover financial results, business updates, investor conference participation and capital actions used to fund development activity. Recurring financing news includes public offerings, registered direct offerings, common stock, pre-funded warrants and common stock warrants.
Altimmune (Nasdaq: ALT) will present 24-week Phase 2b IMPACT data for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) at AASLD The Liver Meeting® 2025 in Washington, D.C., Nov 7–11, 2025.
Two late-breaking presentations are scheduled: an oral podium on Nov 11, 2025 at 11:45 a.m. ET by Dr. Mazen Noureddin covering the randomized, placebo-controlled trial (publication 5001), and a late-breaking poster on Nov 8, 2025 from 1:00–2:00 p.m. ET by Dr. Julio Gutierrez showing AI-based digital pathology analysis of liver fibrosis (publication 5025). The company expects to announce 48-week data in Q4 2025 and will post the presentation and poster on its Events page.
Altimmune (NASDAQ:ALT) has appointed Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels brings over 30 years of experience and will lead the clinical development of pemvidutide, including the planned Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH).
He succeeds Scott Harris, M.D., who will remain as Senior Strategic Advisor until February 2026. Dr. Arbet-Engels joins from X4 Pharmaceuticals, where he contributed to the successful approval of Xolremdi. His compensation package includes options to purchase 450,000 shares and 150,000 restricted stock units of Altimmune's common stock.
The appointment comes at a crucial time as Altimmune prepares for upcoming 48-week data from the IMPACT trial in MASH and ongoing Phase 2 trials in Alcohol Use Disorder and Alcohol-associated Liver Disease.Altimmune (NASDAQ:ALT), a late clinical-stage biopharmaceutical company focused on liver and cardiometabolic diseases, has announced its participation in two upcoming investor conferences. Management will present at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025, at 10:30 a.m. ET, and the H.C. Wainwright Liver Disease Virtual Conference on October 21, 2025, at 7:00 a.m. ET.
Both presentations will feature fireside chats and will be available via webcast through the Events section of Altimmune's website. The company's management team will also be available for one-on-one meetings with investors during these events.
Altimmune (NASDAQ:ALT) has appointed Linda M. Richardson as Chief Commercial Officer, effective September 16, 2025. Richardson brings over 30 years of experience in sales, marketing, and commercial development, with expertise in metabolic disease, hepatology, cardiovascular, and addiction medicine.
Richardson joins Altimmune as the company approaches Phase 3 development of pemvidutide in MASH. She previously served as Chief Commercial Officer at Intercept Pharmaceuticals until early 2024 and held senior positions at Chimerix, Sanofi, Reliant Pharmaceuticals, and GSK.
As part of her compensation package, Richardson will receive options to purchase 278,000 shares and 96,000 restricted stock units (RSUs), with a four-year vesting schedule.
Altimmune (NASDAQ:ALT), a late clinical-stage biopharmaceutical company focused on peptide-based therapeutics for liver and cardiometabolic diseases, has announced its participation in three upcoming investor conferences in September 2025.
The company will attend the Wells Fargo Healthcare Conference in Boston on September 5 for one-on-one meetings, the H.C. Wainwright Global Investment Conference in New York on September 9 with a fireside chat at 8:30 a.m. ET, and the Morgan Stanley Global Healthcare Conference in New York on September 10 with a fireside chat at 7:45 a.m. ET. The fireside chat sessions will be available via webcast on Altimmune's website.
Altimmune (NASDAQ:ALT) has received FDA Fast Track designation for pemvidutide in treating Alcohol Use Disorder (AUD). The company is currently conducting RECLAIM, a Phase 2 trial enrolling approximately 100 patients to evaluate pemvidutide's safety and efficacy in AUD treatment.
The trial, which began in May 2025, will randomize patients 1:1 to receive either 2.4 mg pemvidutide or placebo weekly for 24 weeks. The study's primary endpoint focuses on reducing heavy drinking days, with secondary endpoints including WHO risk drinking level reduction and changes in alcohol intake biomarkers.
AUD affects over 28 million adults in the U.S., with only 2% receiving medication treatment, highlighting a significant unmet medical need. Pemvidutide's potential effectiveness is supported by preclinical studies showing significant reduction in alcohol intake.
Altimmune (NASDAQ:ALT) announced positive results from its IMPACT Phase 2b trial for pemvidutide in MASH treatment. The drug achieved statistically significant MASH resolution in up to 59.1% of patients and demonstrated fibrosis improvement in up to 34.5% of treated patients. New data showed potentially class-leading improvements in corrected T1 (cT1) imaging, with significant decreases of 145.0ms and 147.9ms in the 1.2mg and 1.8mg groups respectively.
The company reported $183.1 million in cash and investments as of June 30, 2025, a 39% increase from December 31, 2024. Altimmune initiated two new Phase 2 trials: RECLAIM for Alcohol Use Disorder and RESTORE for Alcohol-Associated Liver Disease. An End-of-Phase 2 Meeting with FDA is expected in Q4 2025, with full 48-week IMPACT trial data also anticipated in the same quarter.
Altimmune (NASDAQ:ALT) has appointed Jerry Durso as Chairman of the Board of Directors, effective August 12, 2025. The appointment comes as the company prepares for Phase 3 development of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). Durso, who joined the Board in February 2025, succeeds Mitchel Sayare, Ph.D., who will continue serving as an Independent Director.
The leadership transition aligns with Altimmune's planned advancement of pemvidutide, with an End-of-Phase 2 Meeting with the FDA scheduled for Q4 2025. Durso brings over 30 years of life sciences industry experience, most recently serving as CEO of Intercept Pharmaceuticals, where he led the company's successful rare liver disease franchise and its acquisition by Alfasigma.
Altimmune (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, has scheduled its second quarter 2025 financial results announcement for Tuesday, August 12, 2025. The company will host a conference call at 8:30 am ET featuring management discussion of financial results and a business update.
The conference call will be accessible via webcast on Altimmune's Investor Relations website, with dial-in registration available for participants. A replay will be available on the website for up to three months following the call.
Altimmune (NASDAQ:ALT) has initiated the RESTORE Phase 2 trial evaluating pemvidutide for Alcohol-Associated Liver Disease (ALD). The randomized, placebo-controlled study will enroll 100 patients across 34 sites, with patients receiving either 2.4mg pemvidutide or placebo for 48 weeks.
The trial's primary endpoint focuses on changes in liver stiffness measurement at Week 24, with secondary endpoints including measurements at Week 48, Enhanced Liver Fibrosis score changes, and alterations in alcohol consumption and body weight. The study follows FDA clearance of the IND application in January 2025.
Pemvidutide, a novel GLP-1/glucagon dual receptor agonist, targets a significant medical need, as over 6 million Americans with Alcohol Use Disorder have progressed to ALD, a condition currently lacking approved treatments.